Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in ovarian cancer

ABSTRACT: The goal of this study was to investigate molecular pathways associated with PDE10A in ovarian cancer. We used CRISPR/Cas9 to knockout PDE10A in SKOV3 cells. We used the Illumina NextSeq500 to generate between 30-35 million paired end 75bp sequencing reads per sample for transcript level abundance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE164474 | GEO | 2022/01/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Phosphodiesterase 10A inactivation protects against doxorubicin-induced cardiotoxicity and concomitantly inhibits tumor growth

Project description:Phosphodiesterase 10A (PDE10A), by degrading cAMP/cGMP, play critical roles in cardiovascular biology/disease. Cardiotoxicity is a clinical complication of chemotherapy. We aim to determine the role of PDE10A in cancer growth and cardiotoxicity induced by doxorubicin (DOX), a chemotherapy drug. We found that PDE10A deficiency/inhibition alleviated DOX-induced cardiotoxicity in C57Bl/6J mice, including myocardial atrophy, apoptosis, and dysfunction. RNAseq study revealed several PDE10A-regulated signaling associated with DOX-induced cardiotoxicity. In cancer cells, PDE10A inhibition increased the death, decreased the proliferation, and potentiated the effect of DOX in various cancer-cell lines. Importantly, in nude mice with implanted ovarian cancer xenografts, PDE10A inhibition attenuated tumor growth while protected against DOX-induced cardiotoxicity. In isolated cardiomyocytes (CMs), PDE10A contributed to DOX-induced CM death via promoting mitochondrial dysfunction, and to CM atrophy via potentiating foxo3 signaling. Collectively, our study elucidates a novel role for PDE10A in cardiotoxicity and cancer growth in vitro and in vivo, and suggest that PDE10A inhibition may represent a novel strategy in cancer therapy.

2023-06-22 | GSE224157 | GEO

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in ovarian cancer

Project description:Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in ovarian cancer

| PRJNA690803 | ENA

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking ?-catenin and MAPK signaling.

Project description: Not available

| S-EPMC5642477 | biostudies-literature

Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington’s disease models

Project description:Using Huntington’s disease (HD) mouse models that quantitatively replicate the reduction of striatal Phoshodiesterase 10 (PDE10) levels in manifest Huntington’s disease patients, we demonstrate the potential therapeutic benefit of PDE10 inhibition on correcting basal ganglia circuitry deficits thought to drive disease symptomology in patients. PDE10 inhibition acutely restored corticostriatal input and boosted cortically driven indirect pathway activity in HD models with compromised PDE10 levels. We show that cyclic nucleotide signaling processes are impaired in the models, and that elevation of both the cAMP and cGMP nucleotides afforded by PDE10 inhibition are required for this rescue. Global phosphoproteomic profiling of striatal proteins in response to PDE10 inhibition provide novel information on the plausible neural substrates responsible for the improvement. Finally, we show that long-term chronic treatment of the Q175 knock-in mouse model with PDE10A inhibitors, starting at a presymptomatic age, showed improvements, above and beyond those seen during acute administration, including a partial reversal of striatal deregulated transcripts predominantly driven through activation of the AP-1 and CREB transcription factor complexes, and a prevention of the emergence of some cardinal HD neurophysiological deficits.

2016-12-02 | PXD005138 | Pride

Epigenome Mapping in pancreatic cancer cells

Project description:Genome binding/occupancy profiling of H3K4me1 and H3K4me3 upon KMT2D depletion was performed by Illumina NextSeq500 using single‐end 75bp protocol.

2018-08-20 | GSE85886 | GEO

Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling.

Project description: Not available

| S-EPMC3073929 | biostudies-literature

Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and ?-catenin-dependent TCF transcriptional activity.

Project description: Not available

| S-EPMC4212019 | biostudies-literature

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.

Project description: Not available

| S-EPMC7689203 | biostudies-literature

Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats.

Project description: Not available